fashion -WSS

fashion

author：leisure time 2025-10-02 19:20:50 - browse：92655

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

WSS

CDC overhauls leadership of center that led response to Covid

The thinking behind the controversial eating disorder chatbot Tessa

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Biogen nominates mother of director’s child to replace him on board

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

The history of OxyContin, told through Purdue Pharma documents

explore

fashion

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Covid's long

Sports medicine is finally prioritizing gender equality

Novo pauses ads for weight loss drug Wegovy amid demand

Peter Hotez and the public health issue of online harassment

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Medical records are filled with copy

Large hospital system sues Multiplan for low

Cancer drug shortages should be causing more outrage

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

explore

Can medical device makers keep up in the race to treat obesity?

The history of OxyContin, told through Purdue Pharma documents

GOP presidential candidates start declaring their loyalty

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Senate panel passes drug pricing bills, but drops one PBM reform

Novo: Oral version of Ozempic leads to 15% weight loss

knowledge

hotspot

hotspot

focus